MIV 701

Drug Profile

MIV 701

Alternative Names: MIV-701

Latest Information Update: 08 Nov 2010

Price : $50

At a glance

  • Originator Medivir AB
  • Class Antirheumatics; Osteoporosis therapies; Small molecules
  • Mechanism of Action Cathepsin K inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bone cancer; Osteoarthritis; Osteoporosis

Most Recent Events

  • 01 Sep 2009 Discontinued - Phase-I for Osteoporosis in European Union (PO)
  • 01 Sep 2009 Discontinued - Preclinical for Osteoarthritis in Sweden (PO)
  • 01 Sep 2009 Discontinued - Preclinical for Bone cancer in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top